 | • レポートコード：MRC2Q12-17957 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療機器＆消耗品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、重症筋無力症診断試薬/機器のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 重症筋無力症診断試薬/機器のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 重症筋無力症診断試薬/機器の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 重症筋無力症診断試薬/機器のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの重症筋無力症診断試薬/機器の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の重症筋無力症診断試薬/機器の売上および2028年までの予測に焦点を当てています。 重症筋無力症診断試薬/機器のグローバル主要企業には、Argenx SE、American Regent、Abcam、Sigma-Aldrich、BioAssay Systems、Attogene、Cambridge Bioscience、Invitrogen、Assay Genie、Neuro Medical Equipment, Inc.、Medtronic、Nihon Kohden、Natus Medical、Compumedics、Philips Healthcare、Micromed S.p.A.、Wuhan Huamei Biological Engineering Co., Ltd.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 重症筋無力症診断試薬/機器市場は、タイプとアプリケーションによって区分されます。世界の重症筋無力症診断試薬/機器市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 検出試薬、EMG装置 【アプリケーション別セグメント】 病院、専門外来、研究機関、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 重症筋無力症診断試薬/機器製品概要 - タイプ別市場（検出試薬、EMG装置） - アプリケーション別市場（病院、専門外来、研究機関、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の重症筋無力症診断試薬/機器販売量予測2017-2028 - 世界の重症筋無力症診断試薬/機器売上予測2017-2028 - 重症筋無力症診断試薬/機器の地域別販売量 - 重症筋無力症診断試薬/機器の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別重症筋無力症診断試薬/機器販売量 - 主要メーカー別重症筋無力症診断試薬/機器売上 - 主要メーカー別重症筋無力症診断試薬/機器価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（検出試薬、EMG装置） - 重症筋無力症診断試薬/機器のタイプ別販売量 - 重症筋無力症診断試薬/機器のタイプ別売上 - 重症筋無力症診断試薬/機器のタイプ別価格 ・アプリケーション別市場規模（病院、専門外来、研究機関、その他） - 重症筋無力症診断試薬/機器のアプリケーション別販売量 - 重症筋無力症診断試薬/機器のアプリケーション別売上 - 重症筋無力症診断試薬/機器のアプリケーション別価格 ・北米市場 - 北米の重症筋無力症診断試薬/機器市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症診断試薬/機器市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの重症筋無力症診断試薬/機器市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症診断試薬/機器市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の重症筋無力症診断試薬/機器市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症診断試薬/機器市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の重症筋無力症診断試薬/機器市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症診断試薬/機器市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの重症筋無力症診断試薬/機器市場規模（タイプ別、アプリケーション別） - 主要国別の重症筋無力症診断試薬/機器市場規模（トルコ、サウジアラビア） ・企業情報 Argenx SE、American Regent、Abcam、Sigma-Aldrich、BioAssay Systems、Attogene、Cambridge Bioscience、Invitrogen、Assay Genie、Neuro Medical Equipment, Inc.、Medtronic、Nihon Kohden、Natus Medical、Compumedics、Philips Healthcare、Micromed S.p.A.、Wuhan Huamei Biological Engineering Co., Ltd. ・産業チェーン及び販売チャネル分析 - 重症筋無力症診断試薬/機器の産業チェーン分析 - 重症筋無力症診断試薬/機器の原材料 - 重症筋無力症診断試薬/機器の生産プロセス - 重症筋無力症診断試薬/機器の販売及びマーケティング - 重症筋無力症診断試薬/機器の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 重症筋無力症診断試薬/機器の産業動向 - 重症筋無力症診断試薬/機器のマーケットドライバー - 重症筋無力症診断試薬/機器の課題 - 重症筋無力症診断試薬/機器の阻害要因 ・主な調査結果 |
At present, serological antibodies and electrophysiological examinations provide the main basis for the diagnosis of MG, including single-fiber electromyography (the highest sensitivity, about 99%), serum antibody detection (high specificity, ocular muscle type sensitivity is about 50%, systemic type 85%), repetitive electrical stimulation (lower sensitivity when detecting proximal muscles, about 76%). AchEI can be used to help support the diagnosis of MG, and based on its clinical response, it can indicate a positive response to long-term treatment, but its current application is limited due to objectivity defects and false positives. Edrophonium testing can cause life-threatening complications that may require urgent resuscitation and is currently/banned in Italy and several other countries. In contrast, the neostigmine trial was more safe and reliable.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Myasthenia Gravis Diagnostic Reagents and Equipment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Myasthenia Gravis Diagnostic Reagents and Equipment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Myasthenia Gravis Diagnostic Reagents and Equipment is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Myasthenia Gravis Diagnostic Reagents and Equipment include Argenx SE, American Regent, Abcam, Sigma-Aldrich, BioAssay Systems, Attogene, Cambridge Bioscience, Invitrogen and Assay Genie, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Myasthenia Gravis Diagnostic Reagents and Equipment manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Myasthenia Gravis Diagnostic Reagents and Equipment market. Further, it explains the major drivers and regional dynamics of the global Myasthenia Gravis Diagnostic Reagents and Equipment market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Argenx SE
American Regent
Abcam
Sigma-Aldrich
BioAssay Systems
Attogene
Cambridge Bioscience
Invitrogen
Assay Genie
Neuro Medical Equipment, Inc.
Medtronic
Nihon Kohden
Natus Medical
Compumedics
Philips Healthcare
Micromed S.p.A.
Wuhan Huamei Biological Engineering Co., Ltd.
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Myasthenia Gravis Diagnostic Reagents and Equipment Segment by Type
Detection reagent
EMG equipment
Myasthenia Gravis Diagnostic Reagents and Equipment Segment by Application
Hospital
Specialist Outpatient Clinic
Research Institutions
Other
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Myasthenia Gravis Diagnostic Reagents and Equipment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Myasthenia Gravis Diagnostic Reagents and Equipment, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Myasthenia Gravis Diagnostic Reagents and Equipment, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Myasthenia Gravis Diagnostic Reagents and Equipment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Myasthenia Gravis Diagnostic Reagents and Equipment sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Myasthenia Gravis Diagnostic Reagents and Equipment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Myasthenia Gravis Diagnostic Reagents and Equipment sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Argenx SE, American Regent, Abcam, Sigma-Aldrich, BioAssay Systems, Attogene, Cambridge Bioscience, Invitrogen and Assay Genie, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Myasthenia Gravis Diagnostic Reagents and Equipment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Myasthenia Gravis Diagnostic Reagents and Equipment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Myasthenia Gravis Diagnostic Reagents and Equipment sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Myasthenia Gravis Diagnostic Reagents and Equipment Product Introduction
1.2 Market by Type
1.2.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Detection reagent
1.2.3 EMG equipment
1.3 Market by Application
1.3.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Specialist Outpatient Clinic
1.3.4 Research Institutions
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales Estimates and Forecasts 2017-2028
2.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue Estimates and Forecasts 2017-2028
2.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Region
2.4.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Region (2017-2022)
2.4.2 Global Sales Myasthenia Gravis Diagnostic Reagents and Equipment by Region (2023-2028)
2.5 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Region
2.5.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Region (2017-2022)
2.5.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Manufacturers
3.1.1 Global Top Myasthenia Gravis Diagnostic Reagents and Equipment Manufacturers by Sales (2017-2022)
3.1.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Myasthenia Gravis Diagnostic Reagents and Equipment in 2021
3.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Manufacturers
3.2.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Manufacturers (2017-2022)
3.2.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Myasthenia Gravis Diagnostic Reagents and Equipment Revenue in 2021
3.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Type
4.1.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Historical Sales by Type (2017-2022)
4.1.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Forecasted Sales by Type (2023-2028)
4.1.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales Market Share by Type (2017-2028)
4.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Type
4.2.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Historical Revenue by Type (2017-2022)
4.2.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Forecasted Revenue by Type (2023-2028)
4.2.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue Market Share by Type (2017-2028)
4.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Price by Type
4.3.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Price by Type (2017-2022)
4.3.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Application
5.1.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Historical Sales by Application (2017-2022)
5.1.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Forecasted Sales by Application (2023-2028)
5.1.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Sales Market Share by Application (2017-2028)
5.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Application
5.2.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Historical Revenue by Application (2017-2022)
5.2.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Forecasted Revenue by Application (2023-2028)
5.2.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Revenue Market Share by Application (2017-2028)
5.3 Global Myasthenia Gravis Diagnostic Reagents and Equipment Price by Application
5.3.1 Global Myasthenia Gravis Diagnostic Reagents and Equipment Price by Application (2017-2022)
5.3.2 Global Myasthenia Gravis Diagnostic Reagents and Equipment Price Forecast by Application (2023-2028)
6 North America
6.1 North America Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Type
6.1.1 North America Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Type (2017-2028)
6.1.2 North America Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Type (2017-2028)
6.2 North America Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Application
6.2.1 North America Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Application (2017-2028)
6.2.2 North America Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Application (2017-2028)
6.3 North America Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Country
6.3.1 North America Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Country (2017-2028)
6.3.2 North America Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Type
7.1.1 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Type (2017-2028)
7.1.2 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Type (2017-2028)
7.2 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Application
7.2.1 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Application (2017-2028)
7.2.2 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Application (2017-2028)
7.3 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Country
7.3.1 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Country (2017-2028)
7.3.2 Europe Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Type
8.1.1 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Type (2017-2028)
8.1.2 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Type (2017-2028)
8.2 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Application
8.2.1 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Application (2017-2028)
8.2.2 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Application (2017-2028)
8.3 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Region
8.3.1 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Region (2017-2028)
8.3.2 Asia Pacific Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Type
9.1.1 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Type (2017-2028)
9.1.2 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Type (2017-2028)
9.2 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Application
9.2.1 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Application (2017-2028)
9.2.2 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Application (2017-2028)
9.3 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Country
9.3.1 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Country (2017-2028)
9.3.2 Latin America Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Type
10.1.1 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Type (2017-2028)
10.1.2 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Type (2017-2028)
10.2 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Application
10.2.1 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Application (2017-2028)
10.2.2 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Application (2017-2028)
10.3 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Market Size by Country
10.3.1 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Sales by Country (2017-2028)
10.3.2 Middle East and Africa Myasthenia Gravis Diagnostic Reagents and Equipment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Argenx SE
11.1.1 Argenx SE Corporation Information
11.1.2 Argenx SE Overview
11.1.3 Argenx SE Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Argenx SE Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Argenx SE Recent Developments
11.2 American Regent
11.2.1 American Regent Corporation Information
11.2.2 American Regent Overview
11.2.3 American Regent Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 American Regent Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 American Regent Recent Developments
11.3 Abcam
11.3.1 Abcam Corporation Information
11.3.2 Abcam Overview
11.3.3 Abcam Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Abcam Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Abcam Recent Developments
11.4 Sigma-Aldrich
11.4.1 Sigma-Aldrich Corporation Information
11.4.2 Sigma-Aldrich Overview
11.4.3 Sigma-Aldrich Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sigma-Aldrich Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sigma-Aldrich Recent Developments
11.5 BioAssay Systems
11.5.1 BioAssay Systems Corporation Information
11.5.2 BioAssay Systems Overview
11.5.3 BioAssay Systems Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 BioAssay Systems Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 BioAssay Systems Recent Developments
11.6 Attogene
11.6.1 Attogene Corporation Information
11.6.2 Attogene Overview
11.6.3 Attogene Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Attogene Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Attogene Recent Developments
11.7 Cambridge Bioscience
11.7.1 Cambridge Bioscience Corporation Information
11.7.2 Cambridge Bioscience Overview
11.7.3 Cambridge Bioscience Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Cambridge Bioscience Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Cambridge Bioscience Recent Developments
11.8 Invitrogen
11.8.1 Invitrogen Corporation Information
11.8.2 Invitrogen Overview
11.8.3 Invitrogen Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Invitrogen Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Invitrogen Recent Developments
11.9 Assay Genie
11.9.1 Assay Genie Corporation Information
11.9.2 Assay Genie Overview
11.9.3 Assay Genie Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Assay Genie Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Assay Genie Recent Developments
11.10 Neuro Medical Equipment, Inc.
11.10.1 Neuro Medical Equipment, Inc. Corporation Information
11.10.2 Neuro Medical Equipment, Inc. Overview
11.10.3 Neuro Medical Equipment, Inc. Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Neuro Medical Equipment, Inc. Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Neuro Medical Equipment, Inc. Recent Developments
11.11 Medtronic
11.11.1 Medtronic Corporation Information
11.11.2 Medtronic Overview
11.11.3 Medtronic Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Medtronic Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Medtronic Recent Developments
11.12 Nihon Kohden
11.12.1 Nihon Kohden Corporation Information
11.12.2 Nihon Kohden Overview
11.12.3 Nihon Kohden Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Nihon Kohden Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Nihon Kohden Recent Developments
11.13 Natus Medical
11.13.1 Natus Medical Corporation Information
11.13.2 Natus Medical Overview
11.13.3 Natus Medical Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Natus Medical Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Natus Medical Recent Developments
11.14 Compumedics
11.14.1 Compumedics Corporation Information
11.14.2 Compumedics Overview
11.14.3 Compumedics Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Compumedics Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Compumedics Recent Developments
11.15 Philips Healthcare
11.15.1 Philips Healthcare Corporation Information
11.15.2 Philips Healthcare Overview
11.15.3 Philips Healthcare Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Philips Healthcare Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Philips Healthcare Recent Developments
11.16 Micromed S.p.A.
11.16.1 Micromed S.p.A. Corporation Information
11.16.2 Micromed S.p.A. Overview
11.16.3 Micromed S.p.A. Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Micromed S.p.A. Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Micromed S.p.A. Recent Developments
11.17 Wuhan Huamei Biological Engineering Co., Ltd.
11.17.1 Wuhan Huamei Biological Engineering Co., Ltd. Corporation Information
11.17.2 Wuhan Huamei Biological Engineering Co., Ltd. Overview
11.17.3 Wuhan Huamei Biological Engineering Co., Ltd. Myasthenia Gravis Diagnostic Reagents and Equipment Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Wuhan Huamei Biological Engineering Co., Ltd. Myasthenia Gravis Diagnostic Reagents and Equipment Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Wuhan Huamei Biological Engineering Co., Ltd. Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Myasthenia Gravis Diagnostic Reagents and Equipment Industry Chain Analysis
12.2 Myasthenia Gravis Diagnostic Reagents and Equipment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Myasthenia Gravis Diagnostic Reagents and Equipment Production Mode & Process
12.4 Myasthenia Gravis Diagnostic Reagents and Equipment Sales and Marketing
12.4.1 Myasthenia Gravis Diagnostic Reagents and Equipment Sales Channels
12.4.2 Myasthenia Gravis Diagnostic Reagents and Equipment Distributors
12.5 Myasthenia Gravis Diagnostic Reagents and Equipment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Myasthenia Gravis Diagnostic Reagents and Equipment Industry Trends
13.2 Myasthenia Gravis Diagnostic Reagents and Equipment Market Drivers
13.3 Myasthenia Gravis Diagnostic Reagents and Equipment Market Challenges
13.4 Myasthenia Gravis Diagnostic Reagents and Equipment Market Restraints
14 Key Findings in The Global Myasthenia Gravis Diagnostic Reagents and Equipment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer